Session 1294: Prognostic Markers

Cochair(s): H Bartsch, N Phillips
Date: Tue 12 February 2002, Time: 14:00 - 15:30
Location: CIS Auditorium

Oral Presentations

Time Number Title / Authors / Affiliations
14:00 327 Incidental prostate cancer-prognostic factors. A population based-study from Orebro,Sweden with 20 years follow-up.
O Andren, S Andersson, J Johansson
Department of Urology and Department of Pathology, University hospital of Orebro Sweden
14:15 328 Constitutive expression of MHC class II molecules in melanoma cell lines is due to a constitutive transcription of CIITA from its promoter III
V Deffrennes, J Vedrenne, MC Stolzenberg, G Barbieri, F Baton, J Piskurich, J Ting, D Charron, C Alcaide-Loridan
1INSERM U396, Centre de Recherches Biomedicales des Cordeliers, Paris, France, 2Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, Chapel Hill, USA
14:30 329 Expressed gene clusters with distinct prognostic properties of primary breast tumors
K Iwao, R Matoba, S Noguchi, K Kato
1Taisho Laboratory of Functional Genomics, Nara Institute of Science and Technology, Ikoma, and, 2Department of Surgical Oncology, Osaka University Medical School, Osaka, Japan
14:45 330 Regulation of cancer cell proliferation and survival by β 1 integrins
M Fornaro, D Zheng, M Manzotti, G Tallini, LR Languino
Department of Pathology, Department of Pathology, European Institute of Oncology, Yale University School of Medicine, New Haven, and, MD20141 Milan
15:00 331 Expression of UGT2B7, a glucuronosyltransferase implicated in the inactivation of 4-hydroxyestrone, and in maintaining the activity of retinoic acid, is enhanced in human breast carcinoma in situ, but reduced or abrogated in invasive breast cancer.
J Weisz
Pennsylvania State University College of Medicine, Hershey, PA United States
15:15 332 Realities of microsatellite instability in human cancer
S Oda, Y Maehara, K Sugimachi
1Institute for Clinical Research, National Cancer Centre, Fukuoka, Japan, 2Cancer Centre, Kyushu University Hospital, Fukuoka, Japan

Poster Presentations

Number Title / Authors / Affiliations
333 Phenotype modulation of tumor cell growth outlined by cell morphological patterns.
MAA Castro, F Klamt, G Schwartsmann, I Grivicich, JCF Moreira
1Departamento de Bioquimica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Lutheran University of Brazil, Canoas, Brazil, 3SOAD, Comprehensive Cancer Center, Lutheran University of Brazil, Canoas, Brazil
334 A pathology sub-study of putative prognostic markers in colorectal cancer.
Dr SA Grumett, P Quirke, DJ Kerr, M Conkey, J Stahlsmidt, J Barnwell
1Institute for Cancer Studies, University of Birmingham, , 2Department of Pathology, UK c Department of Clinical Pharmacology, University of Leeds, University of Oxford
335 Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population.
ML Santos, AS Sarkis, IN Nishimoto, PhD Nagai
1Departamento de Radiologia, Universidade de Sao Paulo, Brazil, 2Divisão de Clínica Urológica, Depto de Urologia, Brazil, 3Hospital AC Camargo, São Paulo, Brazil
336 Salivary levels of NF-kappa B dependent cytokines of patients with oral squamous cell carcinoma
NL Rhodus, VU Ho, CS Miller, J Burt, F Ondrey
University of Minnesota, Minneapolis, MN
337 *Mutational alterations of connexin 43 associated with advanced stage of progression of human colon cancer
VA Krutovskikh, NA Iaitckil, V DE Popov, MV Dubina
International Agency for Research on Cancer Unit of Gene-Environment Interactions 150 cours Albert Thomas F-69372 Lyon 08, France
338 Prognostic value of the response to induction chemotherapy in patients with locally advanced inoperable urothelial cancer
JW de Beukelaar, TA Splinter, CC Rijt, PI Schmitz, WJ Kirkels
1Department of Medical Oncology, 2Department of Biostatistics, and, 3Department of; Urology of the Erasmus University Medical Centre Rotterdam, the Netherlands
339 Genetic polymorphisms in the tumor necrosis factor (TNF) gene promoter influence non-Hodgkin's lymphoma outcome.
P Juszczynski, E Kalinka, G Salles, G Woszczek, M Borowiec, E Lech-Maranda, L Baseggio, M Kowalski, T Robak, B Coiffier, K Warzocha
1Department of Hematology, 2Department of Clinical Immunology; Medical University of Lodz, Poland, and, 3Service d'Hematologie, Centre Hospitalier Lyon-Sud, Pierre Benite, France
340 Telomerase expression in prostate cancer imprint smears of patients treated with radical prostatectomy
A Bantis, P Athanassiadou, M Gonidi, A Kyriakidis, A Liossi, E Petrakakou, P Athanassiades, A Giannopoulos
a Pathology Laboratory, Cytology Department b Urology Clinic Laiko Hospital, Medical School University of Athens and Urology Clinic Hippocration Hospital, Athens, Greece
341 Telomerase activity and Metallothionein expression in renal cell carcinomas
A Ioakim-Liossi, P Athanassiadou, D Pantazopoulos, P Karakitsos, A Karkabasi, D Karandrea, E Stergiou, E Petrakakou, A Giachnaki, P Athanassiades
Cytopathology Department “Laiko” Hospital, Athens, Greece
342 Low-density SNP chip for pharmacogenetic applications
S Hauch, M Lustig, M Heisinger, S Waschütza, E Schnakenberg
AdnaGen AG, Hannover-Langenhagen, Lower Saxony Germany
343 Tumor-associated genes differentially expressed in breast tumors regarding the presence or absence of estrogen and progesterone receptors
MA Nagai, N Rós, EC Miracca, RLA Silva, AF Carvalho, FB Runza, LFL Reis, MM Brentani
1Departamento de Radiologia, Disciplina de Oncologia da Universidade de São Paulo, São Paulo, Brazil, 2Ludwig Institute for Cancer Research, São Paulo, Brazil
344 Liver transplantation due to hepatocellular carcinoma: prognostic relevance of quantitative DNA ploidy
H Al-Abadi, T Steinmueller, S Jonas, I Rotter, P Neuhaus
Department of Surgery, Charite, Campus Virchow Klinikum, Humboldt University of Berlin
345 A comprehensive investigation of D-Loop mutations in the mitochondrial DNA as potential diagnostic molecular markers for colorectal cancer.
SR Fradley, Genetics
University of Wales Swansea, Swansea, West Glamorgan United Kingdom
346 Osteopontin Expression may be induced by c-Src in Papillary Thyroid Carcinoma
Y Kato, H Zhu, R Tanaka, T Obara, K Sato, T Sawada, M Kobayashi
1Tokyo JapanDepartment of General Surgery, Tokyo Women's Medical University, Shinjuku, First, 2Affiliated Hospital of Anhui Medical University, Anhui, China
347 Rb and p16 expression characterizes two subgroups of gastrointestinal poorly differentiated endocrine carcinomas with different genetic alterations.
S Pizzi, T D'Adda, C Azzoni, D Bassi, L Bottarelli, M Milione, C Bordi
Department of Pathology & Laboratory Medicine - Pathologic Anatomy, University of Parma, Italy
348 READ BY TITLE Immunosensors for determination of carcinoembryonic antigen by using solid-phase immunoassay
H Ju, Z Dai, J Chen
Department of Chemistry, Nanjng University, China
349 Prognostic significance and clinical impact of the Thomsen-Friedenreich antigen in gastrointestinal cancer
U Karsten, Y Cao, SE Baldus, H Shigeoka, G Butschak, A Kramer, S Goletz
1Max Delbrueck Center for Molecular Medicine, Berlin-Buch, Germany, 2German Cancer Research Center, Heidelberg, Germany, 3Department of Pathology, University of Cologne, Cologne, Germany, 4Kinki University School of Medicine, Osaka, Japan, 5Nemod GmbH, Berlin-Buch, Germany
350 *Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men.
C Streckfus, L Bigler, L Copeland
Office of Research, University of Mississippi Medical Center, Jackson, MS
351 Analysis of genetic abnormalities in locally advanced breast carcinomas determined by microsatellite alterations and p53 gene mutations
SF Picard, N Franco, L Hahnel, M Arnal, S Lizard
Laboratory of Molecular Genetic, Centre Georges Francois Leclerc, Dijon, France
352 *Proteomic analysis of beta-catenin during the neoplastic progression from precursor lesions to invasive squamous cell carcinoma of the esophagus
MJ Roth, N Hu, CP Paweletz, M Iwamoto, Y-L Qiao, W-J Li, H Su, DJ Ahnen, SM Dawsey, MD Taylor
1National Cancer Institute, Bethesda, MD, 2Cancer Institute, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China, 3Shanxi Cancer Hospital and Institute, Taiyuan, Shanxi, People’s Republic of China, 4University of Colorado Health Sciences Center, Denver, CO
353 Microsatellite instability in unselected Sardinian patients with endometrial cancer: screening for hMLH1/hMSH2 and PTEN germline mutations
P Baldinu, A Cossu, A Manca, MP Satta, M Pisano, M Casula, S Dessole, A Pintus, F Tanda, G Palmieri
1Institute of Molecular Genetics, C.N.R, Loc. Tramariglio, 07040 Santa Maria La Palma, 2, and, Italy, 3Institute of Pathology, and, Italy, 4Department of Obstetric & Gynecology, University of Sassari, Sassari, Italy
354 Transforming growth factor alpha: a valid surrogate endpoint biomarker?
SW Beenken, H Jr, WF Malone, KI Bland
1Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL, 2Eli Lilly and Co, Indianapolis, IN, 3Division of Cancer Prevention, The National Cancer Institute, Bethesda, MD
355 Accurate detection and identification of Human Papillomavirus genotypes in archival cervical specimens by broad-spectrum PCR and reverse hybridization and the long-term risk identifies risk for development of cervical carcinoma.
WGV Quint, Y van der Graaf, A Molijn, H Doornewaard, B Kleter, L van Doorn, JG van den Tweel
1Delft Diagnostic Laboratory, Delft, and, 2University Medical Center Utrecht, the Netherlands
356 Genetic polymorphisms in the the human leukocyte antigens (HLA DRB) loci and non-Hodgkin's lymphoma outcome.
E Kalinka, P Juszczynski, G Salles, G Woszczek, M Borowiec, E Lech-Maranda, L Baseggio, M Kowalski, T Robak, B Coiffier, K Warzocha
1Department of Hematology, 2Department of Clinical Immunology; Medical University of Lodz, Poland, and, 3Service d'Hematologie, Centre Hospitalier Lyon-Sud, Pierre Benite, France
357 Urinary tissue factor: A potential marker of malignant disease
Dr Bashir, A Lwaleed
Dr Bashir A. Lwaleed, Department of Urology/Surgery, Level F, Central Block, Research Group, Mail point, Southampton University Hospitals NHT Trust
358 TP53, MEK1, XIAP, BCL-2 and BAX as prognostic and predictive factors in ovarian carcinomas treated with platinum-based regimen.
J Kupryjanczyk, T Szymanska, R Madry, G Karpinska, A Rembiszewska, A Timorek, I Ziolkowska, J Stelmachow, J Zielinski, J Markowska
1Department of Molecular Biology and Gynecologic Oncology, Oncology Center, Warsaw, Poznan, 2Department of Pathology and Obstetrics and Gynecology, Medical Academy and Brodnowski Hospital, Warsaw, Poznan, 3Department of Gynecologic Oncology, Medical Academy, Poznan, Poland